Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk of Recurrence Following Surgical Resection
Conditions
Interventions
Imatinib Mesylate
Locations
1
South Korea
Asan Medical Center, University of Ulsan College of Medicine
Seoul, Seoul, South Korea
Start Date
September 7, 2022
Primary Completion Date
April 30, 2030
Completion Date
April 30, 2030
Last Updated
August 8, 2025
NCT06326346
NCT05493215
NCT05440357
NCT06431451
NCT06523582
NCT06507683
Lead Sponsor
Asan Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions